Evolution of GMO requirements for innovative investigational medicinal products upon transition to the EU CTR

By Sabine Ruehle, Pierre Omnes, Kathryn Parsley, Gabriel Bohl, Myra Widjojoatmodjo, Janneke Westra-de Vlieger, Jayne Hunt and
supportive members of the TOPRA Biotech and Clinical Trial SPIN groups2023-05-18T12:58:00

adobestock_203962815_edited_689767-DARKER

The EU CTR replaced the EU CTD on 31 January 2022, which impacts investigational medicinal products that fall under genetically modified organisms (GMO-IMPs). This article discusses the specificities of the new CTR process for GMO-IMPs and updates on the GMO application processes in light of these changes.

This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

Not a TOPRA member yet? Join our global community.

Five great reasons to become a TOPRA member:

Great savings on our events and training.
Be part of our dynamic international community.
Contribute to the profession.
Grow your skills and knowledge.
Take your career to the next level.

Become a member today!

Have you heard what you’re missing? Listen now to the RegRapPod podcast show, for free!